How do Mounjaro and Ozempic compare for A1C reduction?
Mounjaro (tirzepatide) shows greater A1C reductions than Ozempic (semaglutide) in head-to-head trials. In the SURPASS-2 study, patients on Mounjaro 15 mg dropped A1C by 2.3% from baseline (8.4%), compared to 1.9% for Ozempic 1 mg (from 8.2%). Similar gaps appeared across doses: Mounjaro 10 mg reduced A1C by 2.0%, versus 1.9% for Ozempic.[1] These results held in type 2 diabetes patients on metformin, with Mounjaro consistently outperforming by 0.4-0.5% at higher doses.
Real-world data from a 2023 Cleveland Clinic analysis of over 15,000 patients confirmed this: Mounjaro lowered A1C by an average 1.9%, Ozempic by 1.6%.[2]
What drives Mounjaro's edge in A1C control?
Mounjaro is a dual GIP/GLP-1 agonist, targeting two incretin hormones for stronger glucose-dependent insulin secretion and glucagon suppression. Ozempic is a GLP-1 agonist only. This dual mechanism explains Mounjaro's superior glycemic control in trials like SURPASS, where it also led to more patients reaching A1C below 7% (e.g., 82% on Mounjaro 15 mg vs. 66% on Ozempic).[1][3]
Does Mounjaro also beat Ozempic on weight loss alongside A1C?
Yes, with larger weight reductions that indirectly support A1C goals. SURPASS-2 showed Mounjaro 15 mg causing 22.5 lb loss vs. 15.3 lb for Ozempic 1 mg. The Cleveland Clinic study found 15 lb average loss on Mounjaro vs. 10 lb on Ozempic.[1][2]
What do guidelines say about choosing between them?
ADA and EASD guidelines list both as options for type 2 diabetes with A1C above 7-9%, prioritizing GLP-1s like these for cardiovascular benefits. They favor tirzepatide (Mounjaro) for patients needing maximal A1C or weight loss, based on trial data.[4] No head-to-head cardiovascular outcomes trials exist yet.
Are there situations where Ozempic might be preferable?
Ozempic has longer market experience (approved 2017 vs. Mounjaro 2022), a larger evidence base for heart and kidney protection (e.g., SUSTAIN-6, FLOW trials), and weekly dosing at established 2 mg (higher than SURPASS-2's 1 mg).[5] Mounjaro's GI side effects were similar or slightly higher in trials, leading some patients to switch for tolerability.[1]
Cost and insurance coverage vary; Ozempic generics aren't available yet, but both face shortages.
Who makes these drugs and when do patents expire?
Eli Lilly makes Mounjaro; Novo Nordisk makes Ozempic. Key U.S. patents for tirzepatide expire around 2036-2039; semaglutide around 2031-2032, per DrugPatentWatch.com.[6][7] Challenges from Teva and Mylan could accelerate generics.
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
[2] https://consultqd.clevelandclinic.org/real-world-data-shows-favorable-impact-of-tirzepatide
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[4] https://diabetesjournals.org/care/issue/47/Supplement_1
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
[6] https://www.drugpatentwatch.com/p/trademark/MOUNJARO
[7] https://www.drugpatentwatch.com/p/trademark/OZEMPIC